secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-03-15T23:59:59+00:00
Accession:  0001193125-22-076267
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme appoints Dr. Marwan Noel Sabbagh to Board as Class II director
------------------------------------------------------------------------

- Dr. Sabbagh appointed Class II director effective March 14, 2022, term expires at 2024 annual meeting.
- Entitled to $35,000 annual retainer under the company's Outside Director Compensation Policy.
- Received initial equity grant of 22,058 nonstatutory stock options vesting in equal annual installments over three years.
- Entered into standard form indemnification agreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522076267/0001193125-22-076267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522076267/d334395d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-076267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer